HIV 1 News and Research

RSS

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.

23 Feb 2021

Researchers use high-resolution imaging to observe HIV infection process in the cell nucleus

Scientists at EMBL Heidelberg and at the Zentrum für Infektiologie at Heidelberg University Hospital have succeeded for the first time in imaging HIV during transport into the nucleus of an infected cell.

18 Feb 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

HIV: New therapeutic approach to restore the effectiveness of immune cells

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique has identified a therapeutic approach to restore the effectiveness of immune cells.

8 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today.

3 Feb 2021

FDA approves first injectable, complete regimen for HIV-1 infection in adults

The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

21 Jan 2021

Carbon-based nanomaterials as potential COVID-19 treatments

An international team of researchers says that carbon-based nanomaterials (CBNs) could represent promising new approaches to treating coronavirus disease 2019 (COVID-19) pneumonia that is complicated by a secondary bacterial, viral or fungal infection.

19 Jan 2021

Tetherin downregulation by SARS-CoV-2 enhances viral spread

A new preprint research paper published on the bioRxiv server describes the role of a host protein called tetherin in the spread of the novel coronavirus.

10 Jan 2021

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

In a new study, released on the bioRxiv* preprint server, a team of researchers explores the antiviral potential of red blood cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19.

24 Dec 2020

Research shows that people affected with COVID-19 suffer from cognitive effects

More and more evidence is coming out that people with COVID-19 are suffering from cognitive effects, such as brain fog and fatigue.

17 Dec 2020

Supercomputer simulations lead to an important viral inhibitor discovery

University of New Hampshire researchers recently used Comet at the San Diego Supercomputer Center at UC San Diego and Stampede2 at the Texas Advanced Computing Center to identify new inhibitor binding/unbinding pathways in an RNA-based virus.

17 Dec 2020

SARS-CoV-2 RNA can be reverse-transcribed to be part of chimeric viral-human genome

A new study reveals that the genome of SARS-CoV-2 is inserted into the human genome, accounting for the detection of viral RNAs.

16 Dec 2020

IGC researchers receive three out of six European Research Council grants

Since the establishment of the European Research Council in 2008, the IGC has secured 17 of their competitive grants (7 Starting, 8 Consolidator and 2 Advanced).

10 Dec 2020

HIV 'wonder drug' may not be as effective as hoped in sub-Saharan Africa, study suggests

Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs.

1 Dec 2020

Researchers successfully edit SIV virus from genomes of non-human primates

Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates.

1 Dec 2020

Discovery of 'Achilles heel' in protein crucial to HIV virulence could lead to new class of drugs

The discovery of a potential "Achilles heel" in Nef, the protein that is crucial to HIV virulence and its capacity to trigger AIDS, paves the way for the development of a new class of drugs against the virus.

17 Nov 2020

High prevalence of cross-reactive anti-SARS-CoV-2 antibodies in sub-Saharan Africa

A recent study published in the International Journal of Infectious Diseases has explained the lower prevalence of coronavirus disease 2019 (COVID-19) in sub-Saharan Africa compared to that in the US, Europe, and Asia.

15 Nov 2020

MIT researchers unravel the molecular structure of key coronavirus protein

MIT chemists have determined the molecular structure of a protein found in the SARS-CoV-2 virus. This protein, called the envelope protein E, forms a cation-selective channel and plays a key role in the virus's ability to replicate itself and stimulate the host cell's inflammation response.

12 Nov 2020

Antiviral inhibitor DDX42 shows broad activity against Chikungunya, HIV and SARS-CoV-2

By exploiting type 1 interferon's ability to foster an antagonistic cellular environment for viral replication, a research group from France pinpointed DEAD-box RNA helicase DDX42 as an intrinsic inhibitor of HIV, but also other pathogenic viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Chikungunya virus.

29 Oct 2020